Clinical trials: Vascular And Immunologic Diseases
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
RATIONALE: Cyclosporine eye drops may prevent graft-versus-host disease of the eye in patients who have undergone donor stem cell transplant for hematologic cancer or bone marrow failure disorder.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00755040
- Testing
- cyclosporine ophthalmic emulsion
- Where
- 5 sites in United States
- Volunteers
- 164 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Wegener's Granulomatosis
Study of One Protein Implicated in Wegener Disease
The investigators recently showed an abnormal expansion of NK-like CD4+ T cells in Wegener's granulomatosis (WG), mainly in the diffuse vasculitis presentation.
- Trial name
- DAP12WEGENER (NCT01167491)
- Testing
- Physiopathology Endpoint Classification
- Where
- France
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hematologic Malignancy, Stem Cell Transplant
Mosaic Trial for Stem Cell Transplant Recipients
The goal of this clinical trial is to learn if using an intervention website (Mosaic) improves selected patient-reported outcomes in adult blood cancer patients undergoing allogeneic or autologous stem cell transplant, compared…
- Conditions
- Hematologic Malignancy, Stem Cell Transplant, Bone Marrow Transplant, Leukemia
- Trial name
- Mosaic (NCT06960993)
- Testing
- Intervention website, Enhanced Usual Care (Control) Website
- Where
- 3 sites in United States
- Volunteers
- 356 people
- Sponsor
- Northwestern University
Giant Cell Arteritis (GCA)
Cardiac Involvement in Patients With Giant Cell Arteritis
This prospective observational study aims to investigate whether patients with newly diagnosed giant cell arteritis (GCA) show signs of cardiac involvement.
- Trial name
- NCT07031284
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- University Hospital, Bonn
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
The purpose of this study is to find the number of natural killer (NK) cells from non-HLA matched donors that can be safely infused into patients with cancer. NK cells are a form of lymphocytes that defend against cancer cells.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia
- Trial name
- NCT02890758
- Testing
- Natural Killer (NK) Cells, ALT803
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Brenda Cooper, MD
Multiple Myeloma
Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM
The purpose of this study is to evaluate the safety and effectiveness of combination of Chidamide-Lenalidomine-Dexamethasone in relapsed or refractory multiple myeloma patients
- Trial name
- NCT03605056
- Testing
- chidamide, lenalidomide, dexamethasone
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Peng Liu
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)
This phase II MATCH treatment trial identifies the effects of crizotinib in patients whose cancer has a genetic change called ROS1 translocation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439253
- Testing
- Crizotinib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Vasculitis, Behcet's Disease
Vasculitis Pregnancy Registry
The purpose of this study is to learn about the experience of women with vasculitis who become pregnant. In particular, the study will consist of several online surveys to assess 1.
- Conditions
- Vasculitis, Behcet's Disease, CNS Vasculitis, Cryoglobulinemic Vasculitis
- Trial name
- V-PREG (NCT02593565)
- Testing
- Online questionnaires
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Pennsylvania
Multiple Myeloma
Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients
This is Phase 2, open-label, multicentre, non-randomised study evaluating participants with newly diagnosed MM eligible for high-dose therapy.
- Trial name
- TALTEC (NCT06505369)
- Testing
- Daratumumab, Bortezomib, Lenalidomide
- Where
- 7 sites in Denmark, Estonia and 1 more
- Volunteers
- 50 people
- Sponsor
- North Estonia Medical Centre
Multiple Myeloma
Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple Myeloma
This is a single-arm, non-randomized, open-label study to confirm the RP2D (recommended phase 2 dose) of GC012F injection in patients with Relapsed/Refractory multiple myeloma (RRMM).
- Trial name
- NCT05412329
- Testing
- GC012F injection
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai Changzheng Hospital
Waldenstrom Macroglobulinemia
Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia
The purpose of this study is to determine whether epratuzumab provides effective therapy in Waldenström's Macroglobulinemia (WM).
- Trial name
- NCT00113802
- Testing
- Epratuzumab (hLL2- anti-CD22 humanized antibody)
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Gilead Sciences
Multiple Myeloma
A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma
The purpose of the study is to determine if the drug motexafin gadolinium will be an effective treatment for patients who have relapsed or refractory multiple myeloma.
- Trial name
- NCT00096837
- Testing
- Motexafin Gadolinium Injection
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Pharmacyclics LLC.
Systemic Lupus Erythematosus (SLE), Systemic Sclerosis
Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases
This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), including LN and SLE-ITP, Sjogren's Syndrome, etc.
- Conditions
- Systemic Lupus Erythematosus (SLE), Systemic Sclerosis, Sjogren's Syndrome (SS), Inflammatory Myopathy
- Trial name
- NCT07236801
- Testing
- YTS109 cell
- Where
- 2 sites in China
- Volunteers
- 18 people
- Sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd.
Relapsed or Refractory Multiple Myeloma, Other Plasma Cell Diseases
Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases
A Phase I/II Study of LM-305 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
- Trial name
- NCT05647512
- Testing
- LM-305, Dexamethasone
- Sponsor
- LaNova Medicines Limited
Multiple Myeloma
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma
Study CC-93269-MM-001 is an open-label, Phase 1, dose escalation (Part A and C) and expansion (Parts B and D), first-in-human clinical study of CC-93269 in subjects with relapsed and refractory multiple myeloma.
- Trial name
- NCT03486067
- Testing
- CC-93269
- Where
- 34 sites in United States, Germany and 4 more
- Volunteers
- 183 people
- Sponsor
- Celgene
Multiple Myeloma, Plasmocytoma
Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma
Patients with stage-I multiple myeloma are treated with a vaccine made from their own immune cells (dendritic cells) and their own myeloma protein. Vaccinations are given on 5 occasions every 4 weeks.
- Trial name
- NCT00988312
- Testing
- autologous idiotype-protein pulsed dendritic cells
- Where
- Germany
- Volunteers
- 9 people
- Sponsor
- University Hospital Carl Gustav Carus
Multiple Myeloma
The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)
Study design: Randomised, controlled, multi-centre, open-label, phase III trial (with a single intervention registration phase).
- Trial name
- NCT03562169
- Testing
- Ixazomib, thalidomide, & dexamethasone (ITD) re-induction, Conventional autologous stem cell transplant (ASCT-con), Augmented autologous stem cell transplant (ASCT-aug)
- Where
- 91 sites in United Kingdom
- Volunteers
- 406 people
- Sponsor
- University of Leeds
Nodal Lymphoma, Lymphoma With Cutaneous Involvement
Panobinostat Biological Correlates Study
This study is looking at the effects of Panobinostat, an investigational treatment, on cancer cells in patients who have Hodgkin lymphoma (a cancer of the immune system with specific Hodgkin/Reed Sternberg Cells), T-cell lymphoma…
- Conditions
- Nodal Lymphoma, Lymphoma With Cutaneous Involvement, Lymphoma in Leukemic Phase, Marrow Involvement With Lymphoma
- Trial name
- VEG VCA1 (NCT01658241)
- Testing
- panobinostat
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Leukemia, Lymphoma
Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00004145
- Testing
- anti-thymocyte globulin, cyclophosphamide, fludarabine phosphate
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Chicago
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), including LN and SLE-ITP, Sjogren's Syndrome, etc.
- Conditions
- Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Sjogren's Syndrome (SS), Inflammatory Myopathy
- Trial name
- NCT07123519
- Testing
- YTS109 cell
- Where
- China
- Volunteers
- 18 people
- Sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.